LON:CLIN Clinigen Group Share Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Clinigen Group PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 649 +23.00 (+3.67 %) (As of 09/25/2020 12:00 AM ET) Add Compare Share Today's Range 612Now: GBX 649▼ 649.5050-Day Range 612MA: GBX 677.59▼ 72052-Week Range 350.40Now: GBX 649▼ 1,000Volume295,365 shsAverage Volume445,849 shsMarket Capitalization£862.51 millionP/E Ratio63.63Dividend Yield1.24%BetaN/A ProfileAnalyst RatingsChartCompetitorsDividendEarningsInsider TradesHeadlines Clinigen Group plc operates as a specialty pharmaceutical and services company. The company operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines in the Africa and Asia Pacific region. The Unlicensed Medicines segment is involved in sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Trial Segment supplies and manages comparator medicines and services to clinical trials and investigator initiated trials. It offers Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Foscavir, an anti-virals which work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company has a strategic alliance with Cumberland Pharmaceuticals Inc. Clinigen Group plc was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingClinigen Group has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 1,112.50, Clinigen Group has a forecasted upside of 71.4% from its current price of GBX 649.Amount of Analyst CoverageClinigen Group has only been the subject of 3 research reports in the past 90 days. Previous Next 3.9 Community Rank Outperform VotesClinigen Group has received 423 “outperform” votes. (Add your “outperform” vote.)Underperform VotesClinigen Group has received 116 “underperform” votes. (Add your “underperform” vote.)Community SentimentClinigen Group has received 78.48% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Clinigen Group and other stocks. Vote “Outperform” if you believe CLIN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CLIN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldClinigen Group has a dividend yield of 1.24%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthClinigen Group does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Clinigen Group is 78.43%. Payout ratios above 75% are not desirable because they may not be sustainable. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Clinigen Group insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Clinigen Group is 63.63, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 18.39.Price to Earnings Ratio vs. SectorThe P/E ratio of Clinigen Group is 63.63, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.61.Price to Book Value per Share RatioClinigen Group has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.46 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Drug Delivery Sub-IndustryN/A SectorMedical Current SymbolLON:CLIN Previous Symbol CUSIPN/A CIKN/A Webwww.clinigengroup.com Phone+44-1283-495010Debt Debt-to-Equity Ratio102.11 Current Ratio1.54 Quick Ratio1.32Price-To-Earnings Trailing P/E Ratio63.63 Forward P/E Ratio0.25 P/E GrowthN/A Sales & Book Value Annual Sales£504.30 million Price / Sales1.71 Cash FlowGBX 109.83 per share Price / Cash Flow5.91 Book ValueGBX 335.50 per share Price / Book1.93Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees849 Outstanding Shares132,899,000Market Cap£862.51 million Next Earnings DateN/A OptionableNot Optionable GBX 649 +23.00 (+3.67 %) (As of 09/25/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CLIN News and Ratings via Email Sign-up to receive the latest news and ratings for CLIN and its competitors with MarketBeat's FREE daily newsletter. Clinigen Group (LON:CLIN) Frequently Asked Questions How has Clinigen Group's stock been impacted by Coronavirus (COVID-19)? Clinigen Group's stock was trading at GBX 657 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CLIN shares have decreased by 1.2% and is now trading at GBX 649. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Clinigen Group? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clinigen Group in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Clinigen Group. How were Clinigen Group's earnings last quarter? Clinigen Group PLC (LON:CLIN) announced its quarterly earnings data on Thursday, September, 17th. The company reported $65.60 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $63.50 by $2.10. View Clinigen Group's earnings history. How often does Clinigen Group pay dividends? What is the dividend yield for Clinigen Group? Clinigen Group announced a dividend on Thursday, September 17th. Investors of record on Thursday, November 5th will be given a dividend of GBX 5.46 per share on Wednesday, December 2nd. This represents a yield of 0.85%. The ex-dividend date is Thursday, November 5th. This is an increase from Clinigen Group's previous dividend of GBX 2.15. The official announcement can be accessed at this link. View Clinigen Group's dividend history. What price target have analysts set for CLIN? 4 equities research analysts have issued 12 month target prices for Clinigen Group's shares. Their forecasts range from GBX 820 to GBX 1,300. On average, they anticipate Clinigen Group's share price to reach GBX 1,112.50 in the next year. This suggests a possible upside of 71.4% from the stock's current price. View analysts' price targets for Clinigen Group. Who are some of Clinigen Group's key competitors? Some companies that are related to Clinigen Group include 1life Healthcare (ONEM), Inspire Medical Systems (INSP), Insmed (INSM), Evotec (EVT), Global Blood Therapeutics (GBT), Principia Biopharma (PRNB), Fate Therapeutics (FATE), BTG (BTG), ABCAM PLC/ADR (ABCZY), Twist Bioscience (TWST), SAGE Therapeutics (SAGE), PTC Therapeutics (PTCT), Reata Pharmaceuticals (RETA), Nektar Therapeutics (NKTR) and Inari Medical (NARI). View all competitors. What other stocks do shareholders of Clinigen Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Clinigen Group investors own include Comerica (CMA), Honda Motor (HMC), Advanced Accelerator Application (AAAP), Albemarle (ALB), First Hawaiian (FHB), Landec (LNDC), NII (NIHD), RTI International Metals (RTI), General Electric (GE) and NetApp (NTAP). Who are Clinigen Group's key executives? Clinigen Group's management team includes the following people: Mr. Shaun Edward Chilton, CEO & Exec. Director (Age 51)Mr. Nicholas Keher, CFO & DirectorMs. Debra Ainge, Chief Operating OfficerMatt Parrish, Head of Investor RelationsMr. David Bryant, Director of Corp. Devel. What is Clinigen Group's stock symbol? Clinigen Group trades on the London Stock Exchange (LON) under the ticker symbol "CLIN." How do I buy shares of Clinigen Group? Shares of CLIN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Clinigen Group's stock price today? One share of CLIN stock can currently be purchased for approximately GBX 649. How big of a company is Clinigen Group? Clinigen Group has a market capitalization of £862.51 million and generates £504.30 million in revenue each year. Clinigen Group employs 849 workers across the globe. What is Clinigen Group's official website? The official website for Clinigen Group is www.clinigengroup.com. How can I contact Clinigen Group? Clinigen Group's mailing address is Pitcairn House Crown Square, First Avenue, STAFFORDSHIRE, DE14 2WW, United Kingdom. The company can be reached via phone at +44-1283-495010. This page was last updated on 9/26/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
